Kyle Bass’ attacks on multiple Horizon Pharma patents is blocked

Cooley convinced the PTAB to reject multiple inter partes review petitions filed by Kyle Bass and his hedge fund created entity, Coalition for Affordable Drugs VII LLC, challenging the validity of client Horizon Pharma's patents on VIMOVO, an arthritis drug that is responsible for a substantial portion of Horizon's annual revenues.

In rejecting the petitions, the PTAB found that Bass failed to establish a reasonable likelihood of being able to prove that the challenged claims are unpatentable. In the past year, Bass has filed multiple IPRs against drug companies as part of an investment strategy to drive down stock prices.

Related Contacts
Ellen Scordino Partner, Boston
Thomas Blinka Partner, Washington, DC
Susan Krumplitsch Partner, Palo Alto